Table 5.
Ascites and its gross appearance (effect of PACAP receptor antagonists) (mean±SE).
| Group | Volume of ascites (mL) | Ascites amylase(IU/L) | Nucleated cell countof ascites (×108/L) | Saponi-fication (n) | Hemorr-hage (n) |
| Normal control | 213±44/7 | 1.71±1.02/9 | |||
| Caerulein-induced pancreatitis | 39075±50341/3 | 7.54±2.85/4a | |||
| Sodium taurocholate-induced pancreatitis | 3.55±1.86/12 | 11463±5486/10a | 2.9±3.06/8 | 2/12 | 3/12 |
| 10 μg PACAP6-27 | 2000±1273/2 | 3.43±1.22/6a | |||
| 100 μg PACAP6-27 | 600±283/2 | 1.39±0.98/2 | |||
| Caerulein+10 μg PACAP6-27 | 5725±3104/4a | 7.04±4.93/5a | |||
| Caerulein +100 μg PACAP6-27 | 3/1 | 90250±94964/2a | 1.53±0.82/2 | ||
| Sodium taurocholate+10 μg PACAP6-27 | 2.58±0.86/6 | 49467±45529/6a | 2.35±1.81/6 | 1/6 | 3/6 |
| Sodium taurocholate+100 μg PACAP6-27 | 3.42±1.99/6 | 64083±40650/6a | 3.44±1.7/6a | 4/6 | 2/6 |
| 10 μg (4-Cl-D-Phe6, Leu17) VIP | 750±495/2a | 5.52±2.38/4a | |||
| 100 μg (4-Cl-D-Phe6, Leu17) VIP | 201 | 3.4/1 | |||
| Caerulein+10 μg (4-Cl-D-Phe6, Leu17) VIP | 6100±1697/2a | 5.38±2.17/5a | |||
| Caerulein+100 μg (4-Cl-D-Phe6, Leu17) VIP | 217 | 1.06±0.51/3 | |||
| Sodium taurocholate+10 μg (4-Cl-D-Phe6, Leu17) VIP | 2.25±0.88/6 | 32700±13611/6a | 2.25±0.86/6 | 3/6 | |
| Sodium taurocholate+100 μg (4-Cl-D-Phe6, Leu17) VIP | 4.17±1.13/6 | 68817±46943/6a | 2.51±1.5/4 | 2/6 |
a
P<0.05 vs normal control.